Human TAFI
| 9-TAFI-01 | Vial | 50 µg |
| 9-TAFI-01-1 | Vial | 1 mg |
Formulation : 20 mM HEPES, 150 mM NaCl, pH 7.4
Description of the Human TAFI
Activity : 2.0 to 9.2 units/mg MW(Da) : 60 000 Extinction coef. : 14.9 (calculated by cDNA) Isoelectric point : 5.0 Structure : 92 amino acids single chain glycoprotein. N-terminal activation peptide, catalytic domain of 309 amino acids.
Advantages
Frozen product.
Expiry date 1 year.
Plastic tubes.
Discount according to quantities.
Informations
After activation by thrombin, the mature protein negatively regulates fibrinolysis by removing plasminogen binding sites to fibrin. TAFI (Thrombin Activatable Fibrinolysis Inhibitor) is a single chain glycoprotein synthesized by the liver and circulating at a plasma concentration of 50 nM. Thrombin cleaves the zymogen and releases the 92 amino acids activating peptide containing 4 N-glycosylation sites and the plamsinogen recognition site. TAFI plays an important role in the interaction between the fibrinolytic, anticoagulant and procoagulant systems.
